Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165568309> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2165568309 endingPage "4" @default.
- W2165568309 startingPage "4540" @default.
- W2165568309 abstract "Abstract Indicine N-oxide (NSC 132319), the first pyrrolizidine alkaloid to be studied as an antitumor agent in humans, was administered to 29 patients with advanced cancer by 10-min infusion daily for five consecutive days in planned escalations ranging from a daily dose of 0.15 to 3.0 g/sq m. At all doses tested, plasma concentrations of indicine N-oxide exhibited a biphasic decline best approximated by a two-compartment open model. At daily doses up to 1.5 g/sq m, the distributive and postdistributive half-lives of plasma elimination ranged from 0.8 to 3.7 min and from 90.6 to 171.7 min, respectively. Total body clearance ranged from 3.6 to 6.2 ml/min/kg. At the highest dose tested, 3 g/sq m, a striking, and as yet unexplained, increase in the half-life of the initial distribution phase and a decrease in total body clearance were noted. Approximately 40% of the administered dose of indicine N-oxide was eliminated in the urine within 24 hr as unmetabolized drug and 2% as the free base indicine. Dose-limiting toxicity of the drug was reversible leukopenia and/or thrombocytopenia. Repetitive courses of indicine N-oxide had a cumulative effect on the severity of myelosuppression, and prior treatment with a nitrosourea enhanced the hemopoietic toxicity of indicine N-oxide. Other toxicities included mild nausea and vomiting during treatment, reversible increases (≥20% of pretreatment values) in serum creatinine in 11 of 43 courses, and transient alterations in serum glutamic-oxaloacetic transaminase. No objective responses were noted, but five patients with advanced gastrointestinal cancer had stability of disease for at least four months. For subsequent studies of drug activity in patients with solid tumors, we would recommend 3.0 g/sq m daily for five days repeated every five weeks. Indicine N-oxide should be used with great caution, or not at all, in patients treated previously with nitrosoureas or other drugs known to produce cumulative bone marrow toxicity." @default.
- W2165568309 created "2016-06-24" @default.
- W2165568309 creator A5011101496 @default.
- W2165568309 creator A5012529799 @default.
- W2165568309 creator A5030694220 @default.
- W2165568309 creator A5032917850 @default.
- W2165568309 creator A5066722006 @default.
- W2165568309 creator A5071020599 @default.
- W2165568309 date "1979-11-01" @default.
- W2165568309 modified "2023-09-23" @default.
- W2165568309 title "Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans." @default.
- W2165568309 cites W1521545368 @default.
- W2165568309 cites W1529245407 @default.
- W2165568309 cites W1818376423 @default.
- W2165568309 cites W1938956095 @default.
- W2165568309 cites W1973775854 @default.
- W2165568309 cites W2043879608 @default.
- W2165568309 cites W2087392329 @default.
- W2165568309 cites W2095761516 @default.
- W2165568309 cites W2115000453 @default.
- W2165568309 cites W2141461901 @default.
- W2165568309 cites W2143770748 @default.
- W2165568309 cites W2406032370 @default.
- W2165568309 cites W2444300526 @default.
- W2165568309 cites W38165400 @default.
- W2165568309 cites W2118242600 @default.
- W2165568309 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/498086" @default.
- W2165568309 hasPublicationYear "1979" @default.
- W2165568309 type Work @default.
- W2165568309 sameAs 2165568309 @default.
- W2165568309 citedByCount "16" @default.
- W2165568309 countsByYear W21655683092012 @default.
- W2165568309 countsByYear W21655683092013 @default.
- W2165568309 countsByYear W21655683092015 @default.
- W2165568309 countsByYear W21655683092019 @default.
- W2165568309 crossrefType "journal-article" @default.
- W2165568309 hasAuthorship W2165568309A5011101496 @default.
- W2165568309 hasAuthorship W2165568309A5012529799 @default.
- W2165568309 hasAuthorship W2165568309A5030694220 @default.
- W2165568309 hasAuthorship W2165568309A5032917850 @default.
- W2165568309 hasAuthorship W2165568309A5066722006 @default.
- W2165568309 hasAuthorship W2165568309A5071020599 @default.
- W2165568309 hasConcept C112705442 @default.
- W2165568309 hasConcept C126322002 @default.
- W2165568309 hasConcept C2780580376 @default.
- W2165568309 hasConcept C2780852908 @default.
- W2165568309 hasConcept C2780873365 @default.
- W2165568309 hasConcept C29730261 @default.
- W2165568309 hasConcept C42219234 @default.
- W2165568309 hasConcept C71924100 @default.
- W2165568309 hasConcept C98274493 @default.
- W2165568309 hasConceptScore W2165568309C112705442 @default.
- W2165568309 hasConceptScore W2165568309C126322002 @default.
- W2165568309 hasConceptScore W2165568309C2780580376 @default.
- W2165568309 hasConceptScore W2165568309C2780852908 @default.
- W2165568309 hasConceptScore W2165568309C2780873365 @default.
- W2165568309 hasConceptScore W2165568309C29730261 @default.
- W2165568309 hasConceptScore W2165568309C42219234 @default.
- W2165568309 hasConceptScore W2165568309C71924100 @default.
- W2165568309 hasConceptScore W2165568309C98274493 @default.
- W2165568309 hasIssue "11" @default.
- W2165568309 hasLocation W21655683091 @default.
- W2165568309 hasOpenAccess W2165568309 @default.
- W2165568309 hasPrimaryLocation W21655683091 @default.
- W2165568309 hasRelatedWork W1978955171 @default.
- W2165568309 hasRelatedWork W1985600349 @default.
- W2165568309 hasRelatedWork W1986971083 @default.
- W2165568309 hasRelatedWork W1997336054 @default.
- W2165568309 hasRelatedWork W2046619319 @default.
- W2165568309 hasRelatedWork W2050726565 @default.
- W2165568309 hasRelatedWork W2099212933 @default.
- W2165568309 hasRelatedWork W2799728947 @default.
- W2165568309 hasRelatedWork W2910938039 @default.
- W2165568309 hasRelatedWork W4200330051 @default.
- W2165568309 hasVolume "39" @default.
- W2165568309 isParatext "false" @default.
- W2165568309 isRetracted "false" @default.
- W2165568309 magId "2165568309" @default.
- W2165568309 workType "article" @default.